A new report published by Allied Market Research titled, “Asthma and COPD Drugs Market by Disease and Medication Class – Global Opportunity Analysis and Industry Forecasts, 2014-2022”, projects that the global market for Asthma and COPD Drugs was valued at $38,960 million in 2015 and would reach $50,359 million by 2022, registering a CAGR of 3.7% from 2016 to 2022. Asthma segment dominated the market in 2015 and expected to continue its dominance throughout the forecast period. North America accounted around for around half of the Global Asthma and COPD Drugs market share in 2015.
Increase in incidence and prevalence of asthma and COPD, growing geriatric population, technological advancement in the treatment of asthma and COPD diseases, growth in initiatives implemented by the government and non-government associations around the Global are the factors that majorly drive the growth of this market. However, stringent government regulations for the product approval, patent expiry of branded drugs, and side effects associated with drugs restrict the market growth.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-free-sample/311
In 2015, the asthma segment accounted for over 65% share of the overall Asthma and COPD Drugs market. Increase in introduction of generic drugs, and rising prevalence of asthma coupled with geriatric population and changes in lifestyle are the major factors that attribute to the rise in growth of this market.
Among the medication classes, the combination products segment held major share of the Global COPD and asthma drug market in 2015. This segment is expected to maintain its leading position in the overall market throughout the analysis period, primarily because of increase in focus on the effective asthma and COPD management and increase in the research and development of innovative treatment of the diseases.
North America led the market share in 2015, and is expected to maintain this lead throughout the forecast period. The growth in the Asthma and COPD Drugs market in these regions attributes to the increase in the asthma and COPD patients, technological advancement in the treatment. However, Asia-Pacific is projected to be the fastest-growing region, registering a CAGR of 5.1% during the analysis period. This is mainly due to the increase in adoption rate for the technological advancement for treating asthma and COPD diseases. In addition, increase in research outsourcing from emerging markets, improvement of healthcare infrastructures, and increase in expenditures in the emerging markets (such as India and China) have boosted the market growth.
Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/311
The key players in the Asthma and COPD Drugs market are highly focused on expanding their business operations in the fast-growing emerging countries with new product launches as the preferred strategy. The key players profiled in this report include GlaxoSmithKline (GSK) (U.K), Novartis AG (Switzerland), Merck & Co. (U.S), Abbott Laboratories (U.S), Boehringer Ingelheim (Germany), AstraZeneca (U.K), Roche Holding AG (Switzerland), Teva Pharmaceutical Industries(Israel), Vectura Group (U.K), and Pfizer Inc. (U.S).
Read similar market research reports on Pharmaceuticals at: https://www.alliedmarketresearch.com/life-sciences/Pharmaceuticals-market-report
Global Analgesics Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $26.4 billion by 2022, registering a CAGR of 7.7% during the period 2015-2022. The non-opioids segment would continue to be the highest revenue-generating segment throughout the forecast period. North America and Europe, are likely to continue their lead through 2022; they collectively accounted for over half of the overall market share in the global analgesics market in 2015.
Frequent pain and aches experienced by the ageing population, increasing incidences of cardiovascular disease (CVD), cancer, & arthritis, and rising investments in R&D by the public & private sectors, with key focus on the classes of compounds to formulate new therapeutics, are the major factors boosting the market growth. However, factors such as uncontrolled prescriptions of opioids and drug abuse, leading to approximately 28,000 deaths in the U.S. every year, and insufficient regulatory guidelines, especially against opioid analgesics, are likely to impede the market growth. Furthermore, the increase in popularity of personalized medicine is expected to provide numerous growth opportunities for the analgesics market in the near future.
Do Enquiry for Sample Report @ https://www.alliedmarketresearch.com/request-free-sample/1254
North America accounted for a major share of the overall analgesics market revenue in 2015, owing to a large number of pharmaceutical companies in this region. The analgesics market in developing economies, such as China and India, has numerous growth opportunities because of the availability of cheap raw materials and economical workforce. The global analgesics manufacturers are relocating their facilities into developing economies by agreements or acquisitions with local players. Moreover, increasing use of analgesics in countries such as Nigeria, China, and India supports the growth of analgesics in developing economies.
The key companies profiled in the report are Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi S.A.
Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/1254
Stress is the Driving Factor of the Male Infertility Market, Takes the Market to $301.5 Million, Globally, by 2020
Geographically, male infertility is segmented in to North America, Europe, Asia Pacific and RoW. The geographic market would be dominated by the North American region by 2020. This is due to the increased adoption of newer techniques such as DNA fragmentation in the routine analysis test for male infertility. The Asia Pacific and RoW region are expected to have the highest CAGR during the analysis period. This is due to the increase in male infertility awareness and rising awareness about the treatments that are available.
Male Infertility Market Report, published by Allied Market Research, forecasts that the global market is expected to garner $301.5 million by 2020, registering a CAGR of 5% during the period 2014-2020.
Read more about this report: https://www.alliedmarketresearch.com/male-infertility-market
Infertility in male is characterized by various infertility related problems such as low sperm count, presence of low motile sperm or azoospermia. The various causes of male infertility include stress, consumption of alcohol or drugs, smoking, obesity, environmental toxins, etc. These factors also act as driving factors of the male infertility market. When an individual is diagnosed with infertility, the person undergoes immense stress, embarrassment and guilt, which would further intensify the infertility problem. This is a major limitation of this market. The opportunity for the growth of this market
is the increase in awareness levels among men and rising trend in medical tourism.
The male infertility market is segmented based on techniques, namely DNA fragmentation, oxidative stress analysis, sperm agglutination test, sperm penetration test, microscopic examination, computer assisted semen analysis and others. The DNA
fragmentation would be the highest revenue generating market by 2020 and is also expected to have the highest CAGR during the analysis period, when compared to the other segments in the techniques market. This is due to the accuracy level the test provides in identifying the level of infertility by measuring the level of DNA damage.
The key companies profiled in the report are ASKA Pharmaceutical Co. Ltd, ZydusCadila Healthcare Limited, Access Pharmaceuticals, Inc., Intas Pharmaceuticals Ltd., Pantarhei Bioscience B, Cordex Pharma, Inc., Merck Serono, Halotech DNA SL, SCSA diagnostics, Andrology Solutions.
Male Infertility Market Segments covered in the report:
- By Techniques
DNA Fragmentation Technique
Oxidative Stress Analysis
Sperm Penetration Assay
Computer Assisted Semen Analysis
- By Geography
Global Smart Inhalers Market states that the market was $5.8 million in 2015 and is expected to reach $191 million by 2022, growing at a CAGR of 63.3% from 2016 to 2022, according to new research published by Allied Market Research. The inhalers segment captured majority share in 2015, whereas nebulizers segment is projected to grow at fastest CAGR of 64.1% during the forecast period. North America, which accounted for around two-fifths share in 2015, is expected to maintain its lead throughout.
Smart inhalers promote adherence to inhalers and also send timely reminders to patients to take their inhaler dose at the required time due to which it has emerged as a novel approach in asthma and COPD management. The major factors that drives the smart inhalers market include worldwide growth in population susceptible to indoor air pollutants, inclination of patients towards digitalized medical devices for monitoring daily medication doses, and rise in prevalence of asthma and COPD. In addition, improved smart inhalers adherence rate and increase in collaboration between pharmaceutical companies and smart inhaler manufacturers promotes technological advancements which would ultimately support the market growth. These smart inhalers directly transfer medication data to the mobile application as well as to the cloud server connected through the internet. Thus, assuring doctor on exact medicine intake and frequency of the same. However, data privacy and limited availability of smart inhalers across regions acts as a major limitation in the market growth.
Read more details of the report at: https://www.alliedmarketresearch.com/smart-inhalers-market
Smart inhaler products comprise sensors that can be easily attached on the traditional inhalers and nebulizers. The inhalers segment accounted for major share of the overall market, as inhalers are preferred as first option of treatment, portability, and cost effectiveness leading to volume sales. However, nebulizers are expected to grow at the fastest rate due to technological advancements that result in their portability and ease of use.
North America accounted for the majority of the revenue in 2015 owing to the increased adoption of smart inhalers and increased awareness about asthma and COPD treatment. Asia-Pacific is projected to be the fastest growing region throughout the analysis period with major revenue contribution from China. Improvement in healthcare infrastructure and increase in healthcare expenditure in the emerging markets (such as India and China) is projected to fulfill the unmet medical needs thus, fueling the smart inhalers market growth in the Asia-Pacific region.
Key findings of the smart inhalers market study:
- In the year 2015, inhalers led the global smart inhalers market revenue, and is projected to grow at a CAGR of 63.2%.
- Smart inhalers market for asthma is expected to grow at a CAGR of 62.0%, in terms of revenue, whereas for COPD, is expected to grow at a CAGR of 64.5%.
- COPD indication segment is expected to grow at a CAGR of 64.5% due to increase in COPD incidence rate, rise in adherence rate.
- The majority of smart inhalers are used by R&D centers and this trend is expected to be continued during the forecast period.
- Europe and Asia-Pacific together accounted for around half of the market share in 2015.
- China is the major shareholder, accounting for about one-third share of the Asia-Pacific smart inhalers market, in terms of value.
- U.S. smart inhalers market is expected to grow at a CAGR of 59.5%.
- German smart inhalers market is expected to grow at a CAGR of 68.2% during analysis period.
Recent developments such as acquisition of Inspiro Medical by Opko Health, collaboration between Novartis and Qualcomm, and acquisition of Gecko Health by Teva pharmaceuticals for manufacturing smart inhalers further signify the increase in competition in the smart inhalers industry. These developments are majorly focused on manufacturing smart inhalers as well as launching new devices with inbuilt smart inhalers instead of using an add on sensor to the device; thereby positively increasing the market revenue as well as competition among the manufacturers.
Request free sample copy of this report at: https://www.alliedmarketresearch.com/request-free-sample/1715
Major players profiled in this report include Vectura Group plc, Adherium Limited, Teva Pharmaceutical Industries Ltd. (Gecko Health Innovations), AstraZeneca plc, Propeller Health, Cohero Health, LLC, Boehringer Ingelheim GmbH, OPKO Health, Inc. (Inspiro Medical Ltd.), GlaxoSmithKline plc, and Novartis AG.
Global Specialty Enzymes Market is Expected to Reach $947.5 Million, by 2020 – Allied Market Research
According to a new report by Allied Market Research titled, “World Specialty Enzymes for Pharmaceuticals, Biotechnology R&D and Diagnostics – Market Opportunity and Forecast, 2014-2020″, the global specialty enzymes market is expected to register a CAGR of 9.4% during 2015-2020. The pharmaceuticals application segment accounted for about half of the overall market share in 2014. The Asia Pacific market would exhibit the highest CAGR of 11.7% during the forecast period (2015-2020).
Specialty enzymes are proteins that act as biocatalysts to accelerate chemical reaction and produce the desired results. Owing to low consumption and high degree of specificity, specialty enzymes are witnessing spurring demand in medical applications such as pharmaceutical, biotechnology research and diagnostics. The growing popularity of specialty enzymes in therapies for chronic diseases such as cancer, cardiovascular diseases, pain and inflammatory disorders among others is the vital force fuelling the market growth. In addition, growing awareness about enzyme-based therapeutics in the Asia Pacific and LAMEA region would further boost the market growth. However, safety concerns due to high vulnerability of enzymes towards contamination, would limit the overall market growth.
A new report published by Allied Market Research titled, “World Excipients Market—Opportunities and Forecasts, 2014–2020,” projects that the world excipients market would reach $6.4 billion by 2020 at a CAGR of 7.6% during 2015 and 2020. Organic chemicals would continue to be the highest revenue-generating segment during the forecast period. North America and Europe will continue to be the lead revenue generating economies through 2020. These regions collectively accounted for about three-fourth of share in the global excipients market in 2015.
Factors that drive the global excipients market are rising demand for pharmaceutical drugs, increasing popularity of functional excipients, drug pipeline, development of novel excipients, and increasing generic drugs market caused by expiration of various bestseller drugs patents. Factors that are likely to impede the market growth include, supply chain issues, high market fragmentation, and implementation of stringent regulations.
DNA sequencing means the process of identifying the precise sequence of nucleotides within DNA molecule. The technology plays a vital role in determining the sequence of four major bases such as thymine, ademine, cytosine and guanine in the DNA strand. Applications of DNA sequencing across has further kept the future of the market robust. Recently, an early pioneer is planning on mapping DNA and use their knowledge on genetics into one it kind blood test, that can pick up early signs of cancer. Furthermore, its application in forensics is increasing owing to the sudden rise in crime rate across different countries.
In a recent discovery, research specialist at the popular National Institute of Standards and Technology have introduced to the world a brand new concept that assures accurate and rapid gene sequencing. Researcher have made this possible by pulling the DNA molecule via a chemically stimulated hole in graphene. Theorist Alex Smolyanitsky at the institute said that “This is essentially a tiny strain sensor.” He added “We did not invent a complete technology. We outlined a new physical principle that can potentially be far superior to anything else out there.”, as published in Eureka Alert. Demand for gene editing that provides dramatic progress, when it comes to speed as well as genetic advancements has always been welcomes in the agricultural sector. CRISPR has finally provided an opportunity for highly modulated GMO governance. The promise as peril offered by CRISPR would open new avenues and boost the food production improvements.
Eyeing huge potential in the DNA sequencing market, an off – the – shelf report publisher has published a report titled “World DNA Sequencing Market – Opportunities and Forecasts, 2014 -2020”. The study further outlines the major drivers, restraints and opportunities that are influencing the global sequencing market. Research analysts designing the report brings to the table how application across Microbial, Consumer and Research, drug discovery would increase.
Enquire about the report @ https://www.alliedmarketresearch.com/purchase-enquiry/163